DDInter1607 DDInter1356
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martidale, The Extra Pharmacopoeia, 31st ed, p121)
Ritonavir {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Oxamniquine
Ritonavir {u} (Compound) resembles {v} (Compound) Lopinavir
Lopinavir {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Oxamniquine
Ritonavir {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Oxamniquine
Ritonavir {u} (Compound) resembles {v} (Compound) Lopinavir
Lopinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abiraterone
Abiraterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxamniquine
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Atomoxetine
Atomoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxamniquine
Ritonavir {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Fesoterodine
Fesoterodine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxamniquine
Ritonavir {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Oxamniquine
Ritonavir {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Fesoterodine
Fesoterodine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxamniquine
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Thioridazine
Thioridazine {u} may lead to a major life threatening interaction when taken with {v} Oxamniquine
Ritonavir {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxamniquine
Ritonavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Oxamniquine (Compound)
Ritonavir (Compound) resembles Lopinavir (Compound) and Lopinavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Oxamniquine (Compound)
Ritonavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Oxamniquine
Ritonavir (Compound) resembles Lopinavir (Compound) and Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Oxamniquine
Ritonavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Atomoxetine (Compound) and Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Oxamniquine
Ritonavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fesoterodine (Compound) and Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Oxamniquine
Ritonavir (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Oxamniquine
Ritonavir (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Fesoterodine (Compound) and Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Oxamniquine
Ritonavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Thioridazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Oxamniquine
Ritonavir (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Oxamniquine